Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Cleft Palate D002972 9 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Contusions D003288 3 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Coronary Vasospasm D003329 9 associated lipids
Cough D003371 19 associated lipids
Death, Sudden D003645 12 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Diseases in Twins D004200 4 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Schelzig H et al. Role of recombinant hirudin in a pig-to-human lung transplantation model. 2002 Transplant. Proc. pmid:12270449
Hashimoto T et al. Experimental study on the relationship between prostaglandin production and acute pancreatic rejection. 1989 Transplant. Proc. pmid:2495617
Jorkasky DK et al. The effects of cyclosporine on human platelet aggregation and thromboxane release. 1989 Transplant. Proc. pmid:2705264
Anderson CB et al. Thromboxane-B2 and renovascular resistance during hypothermic pulsatile perfusion. 1981 Transplant. Proc. pmid:7268892
Kanji VK et al. Vitamin E suppresses cyclosporine A-induced increase in the urinary excretion of arachidonic acid metabolites including F2-isoprostanes in the rat model. 1999 Transplant. Proc. pmid:10331052
García-Valdecasas JC et al. Prostaglandin metabolism and hemodynamic alterations during human liver transplantation. 1993 Transplant. Proc. pmid:8470202
Uchiyama M et al. Comparison between nonpulsatile and pulsatile machine perfusion preservation in liver transplantation from non-heart-beating donors. 2001 Feb-Mar Transplant. Proc. pmid:11267136
Odor-Morales A et al. Increased thromboxane production by the pancreas after 24-hour preservation in UW-1 solution. 1991 Transplant. Proc. pmid:1989317
Kawai T et al. The changes in prostaglandins after segmental pancreatic transplantation. 1991 Transplant. Proc. pmid:1989318
Kin S et al. Effect of preservation on blood flow and production of prostacyclin and thromboxane A2 in canine segmental pancreatic autografts. 1991 Transplant. Proc. pmid:1989320
Quarto Di Palo F et al. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. 1991 Transplant. Proc. pmid:1989347
Saumweber DM et al. The involvement of platelet-activating factor in hyperacute xenogeneic rejection and its modulation by the PAF-antagonist WEB 2086BS. 1991 Transplant. Proc. pmid:1990613
Schultze G et al. Effect of cyclosporine on the generation of prostanoids by cultured peripheral lymphocytes. 1984 Transplant. Proc. pmid:6592863
Foegh ML et al. Urine thromboxane as an immunologic monitor in kidney transplant patients. 1984 Transplant. Proc. pmid:6390872
Foegh ML et al. Monitoring of rat heart allograft rejection by urinary thromboxane. 1984 Transplant. Proc. pmid:6390873
Saumweber DM et al. Studies on xenograft rejection: the role of leukocytes and prostaglandins and their modulation by the hetrazepine WEB 2086BS. 1992 Transplant. Proc. pmid:1566436
Elzinga L et al. Fish oil vehicle for cyclosporine lowers renal thromboxanes and reduces experimental nephrotoxicity. 1987 Transplant. Proc. pmid:3824502
Anderson C et al. Thromboxane synthesis inhibition and renal allograft function. 1989 Transplant. Proc. pmid:2650085
Pepino P et al. LTC4, thromboxane B2 and 6-keto PGF1 in syngeneic and allogenic heterotopic cardiac transplant in rats. 1989 Transplant. Proc. pmid:2650170
Seelos R et al. Prostaglandin synthesis and survival after orthotopic liver transplantation in pigs. 1991 Transplant. Proc. pmid:1926413
Colomer J et al. Thromboxane flux and urinary eicosanoids as an index of reperfusion injury in pancreas transplantation after different periods of cold storage. 1988 Transplant. Proc. pmid:3055474
Pittet JF et al. Protective effect of indomethacin in the development of the postreperfusion syndrome during liver transplantation in pigs. 1991 Transplant. Proc. pmid:1871874
Quereda C et al. Urinary thromboxane B2 and cyclic AMP in cyclosporine-A-treated kidney transplantation. 1994 Transplant. Proc. pmid:7940810
Häyry P et al. Role of thromboxane in the generation of allograft arteriosclerosis in chronic rejection. 1993 Transplant. Proc. pmid:8438433
Weir MR et al. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. 1990 Transplantation pmid:2301025
Nassiri M et al. Lymphoid organ production of immunomodulatory eicosanoids in mice resistant to neonatal tolerance induction. 1994 Transplantation pmid:8009599
Coffman TM et al. Effect of dietary fish oil supplementation on eicosanoid production by rat renal allografts. 1988 Transplantation pmid:3125638
Ogata K et al. Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722. 2001 Transplantation pmid:11374398
Lane NJ et al. Inhibition of leukotriene B4 synthesis does not prevent development of acute renal failure following storage and transplantation. 1994 Transplantation pmid:7809921
Fan TP et al. Mechanism of action of cyclosporine in preventing cardiac allograft rejection. II. Graft tissue levels of prostacyclin and thromboxane. 1987 Transplantation pmid:3547787
Capitanio A et al. Detection of circulating released platelets after renal transplantation. 1982 Transplantation pmid:6461116
Gibbons CP et al. Cortical and vascular prostaglandin synthesis during renal allograft rejection in the rat. 1987 Transplantation pmid:3554639
Garvin PJ et al. Evaluation of the thromboxane A2 synthetase inhibitor OKY-046 in a warm ischemia-reperfusion rat model. 1996 Transplantation pmid:8633364
Balkhy HH et al. Comparison of Eurocollins and University of Wisconsin solution in single flush preservation of the ischemic reperfused lung: an in vivo rabbit model. 1995 Transplantation pmid:7732552
Markewitz A et al. Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation. 1994 Transplantation pmid:8154033
Khirabadi BS et al. Urine immunoreactive thromboxane B2 in rat cardiac allograft rejection. 1985 Transplantation pmid:3880966
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Petric R et al. Amelioration of experimental cyclosporine nephrotoxicity by calcium channel inhibition. 1992 Transplantation pmid:1465778
Johnson BF et al. Urinary thromboxane and 6-keto-prostaglandin F1 alpha are early markers of acute rejection in experimental pancreas transplantation. 1994 Transplantation pmid:7518618
Smith SR et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. 1993 Transplantation pmid:8279014
Proppe DG et al. Diagnostic value of urinary thromboxane B2 concentration in detection of initial acute rejection reactions in human renal allografts. 1995 Transplantation pmid:7709445
Youngelman DF et al. Effects of chronic cyclosporine administration on renal blood flow and intrarenal blood flow distribution. 1991 Transplantation pmid:1994546
Gladue RP and Newborg MF The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats. 1991 Transplantation pmid:1949170
Santillan-Doherty P et al. Urinary thromboxane B2 as an indicator of acute rejection in lung allotransplantation. 1988 Transplantation pmid:3285529
Post S et al. Rapid increase in the activity of enzymes of eicosanoid synthesis in hepatic and extrahepatic tissues after experimental liver transplantation. 1991 Transplantation pmid:1903222
García-Valdecasas JC et al. Prostacyclin, thromboxane, and oxygen free radicals and postoperative liver function in human liver transplantation. 1995 Transplantation pmid:7570973
Hotter G et al. Nitric oxide and arachidonate metabolism in ischemia-reperfusion associated with pancreas transplantation. 1995 Transplantation pmid:7871573
Schnabel FR et al. The relationship of urinary thromboxane excretion to cyclosporine nephrotoxicity. 1991 Transplantation pmid:2006526
Klassen DK et al. Effects of cyclosporine on human renal allograft renin and prostaglandin production. 1989 Transplantation pmid:2660347
Kawaguchi A et al. Increase in urinary thromboxane B2 in rats caused by cyclosporine. 1985 Transplantation pmid:4024243